CL2019002671A1 - Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. - Google Patents
Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.Info
- Publication number
- CL2019002671A1 CL2019002671A1 CL2019002671A CL2019002671A CL2019002671A1 CL 2019002671 A1 CL2019002671 A1 CL 2019002671A1 CL 2019002671 A CL2019002671 A CL 2019002671A CL 2019002671 A CL2019002671 A CL 2019002671A CL 2019002671 A1 CL2019002671 A1 CL 2019002671A1
- Authority
- CL
- Chile
- Prior art keywords
- ire1
- pyridyloxy
- pyrimidinyl
- methods
- stereo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
EN LA PRESENTE SE DESCRIBEN COMPUESTOS DE PIRIMIDINIL-PIRIDILOXI-NAFTILO CON UNA FUNCIÓN O ACTIVIDAD DE MODULACIÓN DE LA ENZIMA REQUIRENTE DE INOSITOL 1 (IRE1), QUE TIENEN LA ESTRUCTURA DE LA FÓRMULA I O I’: O ESTEREOISÓMEROS, TAUTÓMEROS O SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS, Y CON LOS SUSTITUYENTES Y LAS CARACTERÍSTICAS ESTRUCTURALES QUE SE DESCRIBEN EN LA PRESENTE. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS Y MEDICAMENTOS QUE INCLUYEN COMPUESTOS DE FÓRMULA I O I’, ASÍ COMO MÉTODOS DE USO DE DICHOS MODULADORES DE IRE1, SOLOS O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA TRATAR ENFERMEDADES O AFECCIONES QUE SON MEDIADAS POR RECEPTORES DE ESTRÓGENOS, O DEPENDEN DE ELLOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017077059 | 2017-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019002671A1 true CL2019002671A1 (es) | 2019-12-06 |
Family
ID=63522807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002671A CL2019002671A1 (es) | 2017-03-17 | 2019-09-17 | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10968203B2 (es) |
| EP (1) | EP3596063A4 (es) |
| JP (1) | JP6925435B2 (es) |
| KR (1) | KR20190141145A (es) |
| CN (1) | CN111247136A (es) |
| AR (1) | AR111281A1 (es) |
| AU (1) | AU2018233402A1 (es) |
| BR (1) | BR112019019193A2 (es) |
| CA (1) | CA3056833A1 (es) |
| CL (1) | CL2019002671A1 (es) |
| CO (1) | CO2019010078A2 (es) |
| CR (1) | CR20190433A (es) |
| IL (1) | IL269302A (es) |
| PE (1) | PE20191557A1 (es) |
| SG (1) | SG11201908517XA (es) |
| TW (1) | TW201838981A (es) |
| WO (1) | WO2018166528A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018278311B2 (en) | 2017-06-01 | 2021-10-07 | Cornell University | IRE1 small molecule inhibitors |
| US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
| WO2020047518A1 (en) * | 2018-08-30 | 2020-03-05 | The Regents Of The University Of California | Ire1 kinase inhibitors and uses thereof |
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| EP3849663B1 (en) * | 2018-09-12 | 2023-08-02 | Genentech, Inc. | Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use |
| EP3891137B1 (en) * | 2018-12-03 | 2024-10-09 | Cornell University | Ire1 small molecule inhibitors |
| WO2020117634A1 (en) * | 2018-12-03 | 2020-06-11 | Cornell University | Ire1 small molecule inhibitors |
| US20220227730A1 (en) * | 2019-05-15 | 2022-07-21 | Cornell University | Treatment of fibrosis with ire1 small molecule inhibitors |
| CA3188602A1 (en) * | 2020-08-07 | 2022-02-10 | Richard Keenan | Pyrazolopyridine compounds and methods of inhibiting ire1 using same |
| JP2023550049A (ja) | 2020-11-13 | 2023-11-30 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｉｒｅ１アルファ阻害剤及びその使用 |
| EP4243815A4 (en) | 2020-11-13 | 2024-10-02 | Univ California | IRE1ALPHA INHIBITORS AND RELATED USES |
| CN114907350B (zh) * | 2021-02-10 | 2023-12-29 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物、制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005113494A2 (en) * | 2004-05-07 | 2005-12-01 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| EP2340248B1 (en) | 2008-09-15 | 2017-05-31 | The Regents of The University of California | Methods and compositions for modulating ire1, src, and abl activity |
| AU2014247215B2 (en) | 2013-04-04 | 2018-05-10 | Janssen Pharmaceutica Nv | Novel N-(2,3-dihydro-1H-pyrrolo[2,3-b]jpyridin-5-yl)-4- quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4- quinazolinamine derivatives as perk inhibitors |
-
2018
- 2018-03-15 TW TW107108924A patent/TW201838981A/zh unknown
- 2018-03-15 AR ARP180100604A patent/AR111281A1/es unknown
- 2018-03-16 BR BR112019019193A patent/BR112019019193A2/pt not_active Application Discontinuation
- 2018-03-16 KR KR1020197030386A patent/KR20190141145A/ko not_active Application Discontinuation
- 2018-03-16 PE PE2019001893A patent/PE20191557A1/es unknown
- 2018-03-16 AU AU2018233402A patent/AU2018233402A1/en not_active Abandoned
- 2018-03-16 JP JP2019551376A patent/JP6925435B2/ja active Active
- 2018-03-16 SG SG11201908517X patent/SG11201908517XA/en unknown
- 2018-03-16 CA CA3056833A patent/CA3056833A1/en not_active Abandoned
- 2018-03-16 CR CR20190433A patent/CR20190433A/es unknown
- 2018-03-16 EP EP18768363.6A patent/EP3596063A4/en active Pending
- 2018-03-16 WO PCT/CN2018/079292 patent/WO2018166528A1/en active Application Filing
- 2018-03-16 CN CN201880032314.6A patent/CN111247136A/zh active Pending
- 2018-05-24 US US15/989,008 patent/US10968203B2/en active Active
-
2019
- 2019-09-12 IL IL26930219A patent/IL269302A/en unknown
- 2019-09-17 CL CL2019002671A patent/CL2019002671A1/es unknown
- 2019-09-18 CO CONC2019/0010078A patent/CO2019010078A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018166528A1 (en) | 2018-09-20 |
| US10968203B2 (en) | 2021-04-06 |
| AU2018233402A1 (en) | 2019-10-10 |
| JP6925435B2 (ja) | 2021-08-25 |
| IL269302A (en) | 2019-11-28 |
| KR20190141145A (ko) | 2019-12-23 |
| CO2019010078A2 (es) | 2020-01-17 |
| JP2020514377A (ja) | 2020-05-21 |
| US20180265497A1 (en) | 2018-09-20 |
| CR20190433A (es) | 2019-11-20 |
| CN111247136A (zh) | 2020-06-05 |
| BR112019019193A2 (pt) | 2020-04-22 |
| CA3056833A1 (en) | 2018-09-20 |
| PE20191557A1 (es) | 2019-10-24 |
| EP3596063A1 (en) | 2020-01-22 |
| EP3596063A4 (en) | 2020-12-30 |
| TW201838981A (zh) | 2018-11-01 |
| AR111281A1 (es) | 2019-06-26 |
| SG11201908517XA (en) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
| CO2020000145A2 (es) | Carboxamidas como moduladores de los canales de sodio | |
| CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| CL2019000431A1 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814) | |
| UY37098A (es) | Moduladores de ror-gamma | |
| BR112019001923A2 (pt) | moduladores de nmda de espiro-lactama e métodos de sua utilização | |
| DOP2022000115A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CO2018013077A2 (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas | |
| CL2017001364A1 (es) | Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos. | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
| BR112018006259A2 (pt) | "adjunto compressível com estruturas de suporte intermediárias" | |
| BR112018010018A2 (pt) | moduladores de ror-gama | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| CO2022002781A2 (es) | Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos | |
| BR112018073663A2 (pt) | moduladores de receptores nmda spiro-lactâmicos e seus usos | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
| BR112015028613A2 (pt) | análogos de uréia com ligações por pontes substituída como moduladores de sirtuína | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| BR112019001921A2 (pt) | moduladores do receptor nmda de espiro-lactama e seus usos | |
| CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 |